• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza A H1N1 Virus 2009 Synthetic Hemagglutinin and Neuraminidase Peptides for Antibody Detection

tetano

Editor, Senior Moderator
Arch Med Res. 2020 Apr 30. pii: S0188-4409(19)31178-6. doi: 10.1016/j.arcmed.2020.04.011. [Epub ahead of print]
Influenza A H1N1 Virus 2009 Synthetic Hemagglutinin and Neuraminidase Peptides for Antibody Detection.


Avila G[SUP]1[/SUP], Cruz-Licea V[SUP]2[/SUP], Rojas-Espinosa K[SUP]1[/SUP], Berm?dez-?lvarez Y[SUP]1[/SUP], Grostieta E[SUP]1[/SUP], Romero-Valdovinos M[SUP]3[/SUP], Mart?nez-Hern?ndez F[SUP]3[/SUP], Vaughan G[SUP]4[/SUP], Flisser A[SUP]5[/SUP].

Author information




Abstract

BACKGROUND:

Influenza serologic diagnosis is mainly based on hemagglutination inhibition and microneutralization methods, both methods require handling living viruses under an enhanced biosafety level.
AIM:

The current study was performed for developing an ELISA using synthetic peptides to detect influenza A H1N1 virus 2009 specific antibodies in serum and saliva.
METHODS:

Alignments were made with H1N1 hemagglutinin and neuraminidase (HA and NA, respectively) sequences; only conserved sites were used for antigenicity prediction. Two synthetic peptides were assayed; one of neuraminidase (NA15) and one of hemagglutinin (HA-15) and used in ELISA for detecting IgG and IgA antibodies. A cross-sectional study was performed in three municipalities of Mexico City, using negative samples collected before the 2009 influenza outbreak, samples of people who became ill during the outbreak, and samples of the participants in the epidemiological study with or without symptoms.
RESULTS:

The determination of serum IgG antibodies with both peptides allowed differentiating between the post outbreak groups with respect to all others. No differences were found in IgA determination in saliva against both peptides. The frequency of positive participants for NA-15 was 9.5 and 8.8% for HA-15 in serum IgG; whereas the frequency of positive participants for NA-15 was 11%, and for HA-15 was 8.6% for saliva IgA.
CONCLUSIONS:

Synthetic peptides of the neuraminidase and hemagglutinin proteins can be used in ELISA for the determination of IgG and IgA antibodies against the influenza A H1N1 virus 2009.
Copyright ? 2020. Published by Elsevier Inc.



KEYWORDS:

Diagnosis; ELISA; IgA; IgG; Influenza; Mexico city; Synthetic peptides


PMID:32362450DOI:10.1016/j.arcmed.2020.04.011
 
Back
Top Bottom